Emerging treatments
BRAF inhibitors
The squamous papillary variant of craniopharyngioma is often associated with a mutation in the BRAF gene, which may be used as a specific target for pharmacologic treatments. Two case reports of patients with refractory papillary craniopharyngiomas that had BRAF mutations showed significant reduction in tumor volume following treatment with a BRAF inhibitor (either vemurafenib or dabrafenib).[20] Further studies are required to confirm these findings.
Use of this content is subject to our disclaimer